Patients with cancer are at greater risk of developing depression in comparison to the
general population and this is associated with serious adverse effects, such as poorer …

Patients with cancer are more likely to develop depression than the general population,
which negatively impacts their quality of life and prognosis. In order to identify effective …

The prevalence of depressive symptoms in patients with cancer exceeds that observed in
the general population and depression is associated with a poorer prognosis in cancer …

Innate immune activation and inflammation have been posited to play a role in the
pathophysiology of both depression and neoplastic growth. Cancer patients experience a …

New exciting research in psycho-oncology has shed light on the mechanisms by which
biobehavioral signaling in cancer interplays with the neuroimmune axis, as well as on the …

Abstract Major Depressive Disorder (MDD) is common among cancer patients, with
prevalence rates up to four-times higher than the general population. Depression confers …

Depression is a common comorbidity in cancer cases, affecting> 10% of patients. A cancer
diagnosis is life‑changing, and is a source of considerable psychological and emotional …

Depression and cancer commonly co-occur. The prevalence of depression among cancer
patients increases with disease severity and symptoms such as pain and fatigue. The …

Considerable data demonstrate the high prevalence of symptoms of depression in patients
with a wide variety of neoplastic disorders. Moreover, the dire consequences of these …

Depression comorbid with cancer is common and associated with a host of negative health
outcomes. The inflammatory basis of depression is a growing area of research in cancer …